#Cancerdeaths have increased by more than 70% globally over the last 3 decades and are estimated to continue to climb, with more than 18 million cancer deaths projected in 2050. These findings were published in @thelancetoncol.bsky.social.#Cancerdeaths https://bit.ly/42Htid9 #lcsm #gicsm #bcsm

Men with #prostatecancer who closely follow the @americancancersoc.bsky.social cancer survivor guidelines after diagnosis have lower all-cause and cardiovascular mortality compared to those who do not. Published in @jamanetworkopen.com.#prostatecancer https://bit.ly/4nYWww9 #pcsm #gucsm

Findings from the phase 2 ISASOCUT study support the use of subcutaneous isatuximab plus VRd as a new standard of care in newly diagnosed MM, said Dr Arthur Bobin of @chu-poitiers.bsky.social, who presented these results at #IMS25. #IMS2025 #mmsm shorturl.at/iSblj

The AACR Cancer Progress Report 2025 highlights recent advances in cancer research, emphasizing the importance of federal funding. @theaacr.bsky.social Read or listen to our coverage here: shorturl.at/YDWsz

The efficacy of systemic therapy varies among patients with rare #skincancers, but patients with cutaneous adnexal carcinoma have poor outcomes regardless of the therapy they receive. https://bit.ly/42yPlT2 #skcsm

Consolidative radiotherapy at the time of the expected best response to osimertinib was considered well tolerated and demonstrated “promising efficacy” in patients with advanced, EGFR-mutant #NSCLC. From the @eclinicalmed.bsky.social.#NSCLC https://bit.ly/46f62Fq

Taller height may explain a “substantial proportion” of the excess #cancerrisk observed in men, according to researchers. https://bit.ly/4nzq1Fb

Certain patient-reported outcomes can predict OS in patients with #cancer. Published in @jamaoncology.com.#cancer https://bit.ly/4nmpKoW

Dr Rahul Banerjee (@rahulbanerjeemd.bsky.social) of @fredhutch.org shares his favorite presentations from #IMS25. shorturl.at/xaGmE #IMS2025 #mmsm

Teclistamab-based induction regimens have demonstrated efficacy in patients with newly diagnosed multiple myeloma, according to phase 2 trial results presented by @raabms.bsky.social at #IMIS25. shorturl.at/EEQSh #mmsm #ims2025

Completing at least 1 type of adjuvant therapy is associated with “very low” rates of locoregional recurrence in patients aged 50-69 years who underwent lumpectomy for early-stage breast cancer and had low genomic risk, researchers report in @jamanetworkopen.com. shorturl.at/hsfzg #bcsm

Dr Eric K. Singhi (@lungoncdoc.bsky.social) of @mdanderson.bsky.social shares his top 5 presentations from #WCLC25 and explains why he finds them compelling. Read his thoughts here: shorturl.at/ThK4z #lcsm

Daily aspirin use in the adjuvant setting may reduce the risk of recurrence among patients with colorectal cancer who have somatic alterations in the PI3K pathway, according to research published in @nejm.org. shorturl.at/Y6RqF #gicsm #crcsm

New guidelines, created by @ascocancer.bsky.social, @astro-org.bsky.social, and the Society for Surgical Oncology, provide recommendations on the use of postmastectomy radiation therapy in patients with breast cancer. shorturl.at/8TBn4 #bcsm

Active surveillance can be a safe long-term management approach for patients with low-risk papillary #thyroidcancer. Published in @jamasurgery.com.#thyroidcancer https://bit.ly/3VbW55g

New research suggests that female #HCPs with occupational exposure to ionizing radiation may have a higher risk of #breastcancer than their unexposed peers, despite the use of protective equipment. https://bit.ly/4ma46CW #bcsm

ICYMI: Experts say cancer survivors' care can be improved with better coordination between oncologists and primary care providers. Read or listen here:

In surveys of American voters from @theaacr.bsky.social and @ash.hematology.org, most respondents said they support increasing federal funding for #cancer research and other medical research. shorturl.at/w7fbk #OncSky #MedSky

Recent studies in @aacrjournals.bsky.social, @jamadermatology.com, and others have provided new insights that may help inform cancer prevention efforts as well as the treatment of breast, lung, pancreatic, and other cancers. shorturl.at/9UHi3 #OncSky #MedSky

Use of potentially inappropriate medications among #cancer patients is associated with a greater likelihood of frailty, unplanned hospitalization, and death, researchers report. shorturl.at/ugGJH #OncSky

Certain comedications may negatively impact overall survival in patients with advanced #NSCLC receiving pembrolizumab, according to research published in @jamanetworkopen.com. shorturl.at/bjwc6 #lcsm #OncSky

According to research published in @jamaoncology.com, certain patient-reported outcomes can predict overall survival in patients with #cancer. shorturl.at/qMVks #OncSky

The combination of amivantamab and lazertinib can improve overall survival when compared to osimertinib monotherapy in patients with previously untreated, EGFR-mutant, advanced #NSCLC, according to research published in @nejm.org. shorturl.at/ok1Fv #lcsm #OncSky

New data published in @jamanetworkopen.com support the need for “age-based and duration-based anal cancer screening recommendations“ for cervical cancer survivors. shorturl.at/uwwPF #gyncsm #OncSky

Researchers observed an overall increase in the absolute median cost of “best available” guideline-concordant treatments for common solid tumors in the US in 2017-2021, but “minimal relative changes in cost” were seen for therapies that were in use in both 2017 and 2021. shorturl.at/s4MCs #OncSky

First-line treatment with sotorasib, bevacizumab, and chemotherapy demonstrated activity in patients with KRAS G12C-mutant, advanced #NSCLC, according to research presented at #WCLC25. shorturl.at/FpFA2 #lcsm

Adding bevacizumab to neoadjuvant chemo increases the likelihood of optimal cytoreduction in patients with advanced ovarian cancer, but also increases the risk of gastrointestinal perforation, research suggests. shorturl.at/rHNmi #gyncsm #OncSky

Taller height may explain a “substantial proportion” of the excess #cancer risk observed in men, researchers report. shorturl.at/3Xu1N #OncSky #MedSky

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced #NSCLC who had disease progression on first-line osimertinib. Presented at #WCLC25. #lcsm shorturl.at/ADG1h

I spoke to @cancertherapyadv.bsky.social about why cancer survivors can fall through the cracks - and how to prevent it.

With commentary from @ilanayurkiewicz.bsky.social of @stanfordmedicine.bsky.social, @sfuldnasso.bsky.social of Cancer Nation, Dr Kevin Oeffinger of @dukecancer.bsky.social, Dr Tatjana Kolevska of @kaiser-permanente.bsky.social, and more.

Experts say better communication and coordination between oncologists and PCPs are needed to improve care for cancer survivors, but some health care facilities are making progress in that regard. Read or listen here: shorturl.at/8aQYD

Rare pathogenic variants in #cancer predisposition genes increase the risk of developing single and multiple primary cancers. Published in @jamaoncology.com.#cancer https://bit.ly/3I8TGp5

A majority of #cancerdrugs approved in the US during 2019-2022 had “clinical trial uncertainties” that arose from “issues related to trial design, conduct, analysis, or reporting … about drug efficacy and safety,” according to researchers. Reported in @jama.com.#cancerdrugs https://bit.ly/42i4sjz

Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected #colorectalcancer, researchers report. https://bit.ly/4m2IxE3 #gicsm #crcsm

Results from the HARMONi trial suggest the efficacy of ivonescimab + chemo differs between patients in China and those in North America or Europe. Presented at #WCLC25 by Dr Jonathan Goldman of UCLA Health. Discussed by @ramalingammd.bsky.social of @winshipcancer.emory.edu. #lcsm shorturl.at/nijIh

New research shows certain mitochondrial DNA mutations occur before cancer develops and are not always random. These mutations can contribute to therapy resistance in pediatric leukemia. ow.ly/V39G50WViNa

The draft guideline update, #immunotherapy and targeted therapy for advanced gastroesophageal cancer, is now available for open comment. Provide your feedback to us by September 24. #esocsm Learn more: brnw.ch/21wVG8d

Carboplatin plus etoposide, with or without focal treatments, may be safe and effective for patients with high-risk intraocular #retinoblastoma, according to phase 2 trial results. shorturl.at/aY3Xh #pedcsm #OncSky #MedSky

Research suggests that #ChatGPT does not generally provide accurate information when responding to patient questions about hematologic cancers. shorturl.at/yV2GN #leusm #lymsm #mmsm

The rate of death from second primary malignancies has increased among older prostate cancer survivors in the United States, researchers report. shorturl.at/jfuQF #pcsm #gucsm

OS results from FLAURA2 confirm osimertinib + chemo as first-line SOC in EGFRm advanced NSCLC, according to Dr David Planchard of @gustaveroussy.fr. Presented at #WCLC25 shorturl.at/54X73 #lcsm

The efficacy of systemic therapy varies among patients with rare skin cancers, but patients with cutaneous adnexal carcinoma have poor outcomes regardless of the therapy they receive, researchers report. shorturl.at/4cBde #skcsm

Consolidative radiotherapy at the time of the expected best response to osimertinib was considered well tolerated and demonstrated “promising efficacy” in patients with advanced, EGFR-mutant #NSCLC, according to research published in @eclinicalmed.bsky.social. shorturl.at/N8uCW #lcsm

The US contributed more than half of global public and philanthropic #cancer research funding between 2016 and 2023, according to data published in @thelancetoncol.bsky.social, meaning cuts to cancer research funding in the US could have a global impact. shorturl.at/TDzFE

A majority of #cancer drugs approved in the US in 2019-2022 had “clinical trial uncertainties” that arose from “issues related to trial design, conduct, analysis, or reporting … about drug efficacy and safety,” researchers reported in @jama.com. shorturl.at/bQ39T

Adding lenvatinib to treatment with pembrolizumab does not improve outcomes in patients with unresectable, advanced melanoma who have not received prior treatment with PD-(L)1 inhibitors, research suggests. shorturl.at/4fVxp #skcsm #melsm

Adjuvant treatment with NSAIDs can improve disease-free survival and delay recurrence in patients with resected colorectal cancer, researchers report. shorturl.at/5RmfO #gicsm #crcsm #OncSky

#Cancer patients may face multiple legal challenges that impede their access to care. Published in @jamanetworkopen.com.#Cancer https://bit.ly/4ojsFzh

The median overall survival of nearly 4 years appears to be the longest benefit ever reported in a global Phase III clinical trial #FLAURA2 in EGFR-mutated advanced lung cancer #WCLC25 #NSCLC #lcsm #medsky #biosky